10-Q · August 4, 2026
IPG delivered Q2 revenue of $278.580 million, up 11.1% year over year and approximately 5.1% sequentially, while gross margin rose 310 basis points to 40.4%. Industrial Solutions grew 15.7%, but Advanced Solutions fell…
Earnings analysis · 10-Q
IPGP earnings analysis
Filed November 3, 2026 · Our reading of the company's report
The latest report
IPG Photonics delivered strong third-quarter growth, with revenue up 14.6% year over year to $287.5 million, both segments expanding, gross margin improving to 40.7%, and operating cash flow increasing to $78.531…
Read full summary
IPG Photonics delivered strong third-quarter growth, with revenue up 14.6% year over year to $287.5 million, both segments expanding, gross margin improving to 40.7%, and operating cash flow increasing to $78.531 million for the first nine months. However, margin benefited from $5.8 million of tariff recoveries, manufacturing absorption remained pressured, and the company faces a substantial near-term cash outflow of approximately $340.3 million for the Lumibird Medical acquisition. The planned $25 million property impairment and continued cyclicality in the industrial customer base temper the otherwise positive operating trend.
Gross and operating margin
How much of each revenue dollar the business keeps.
One point per quarterly or annual filing. Both margins are shares of that report's revenue.
Where revenue came from
The business segments reported by the company.
Shares of the segments disclosed in this filing, largest first.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Gross margin
- 40.7%
What stood out
-
Revenue and both segments grew
Revenue increased 14.6% year over year to $287.5 million from $250.792 million. Industrial Solutions grew 11.6% to $239.548 million, while Advanced Solutions grew 32.8% to $47.952 million.
-
Gross margin expanded year over year
Gross margin expanded to 40.7% from 39.5% year over year, a 120-basis-point improvement. Tariff activity provided an approximately 170-basis-point gross-margin benefit in the quarter, including $5.8 million of tariff recoveries and $0.8 million of tariff and duty adjustments.
-
Net income improved materially
Net income rose to $20.3 million from $7.5 million year over year, an increase of $12.8 million. The effective tax rate declined to 28.7% from 52.3%.
-
Cash generation improved
Operating cash flow increased to $78.531 million for the first nine months of 2026 from $46.535 million in the prior-year period. Capital expenditures were $54.4 million, implying calculated free cash flow of approximately $24.1 million versus approximately negative $14.4 million in the prior-year period.
-
Liquidity remained strong
Cash and cash equivalents increased to $710.688 million from $403.790 million at December 31, 2025, while working capital increased to $359.131 million from $350.075 million. The company had $224.775 million of unused credit lines and no borrowings under its principal facilities.
-
Industrial demand led growth
Nine-month Industrial Solutions revenue increased 15.9% to $704.181 million, driven by welding, cleaning, cutting and marking. Nine-month Advanced Solutions revenue rose 4.7% to $127.396 million, supported by semiconductor and medical applications.
What to watch
-
Large acquisition cash outflow
The planned Lumibird Medical acquisition is expected to require approximately $340.3 million of cash at closing in Q4 2026, potentially reducing near-term cash balances significantly. Additional contingent consideration could reach $56.7 million.
-
Additional property impairment
The Board approved the sale of certain properties, resulting in a preliminary pre-tax impairment charge of approximately $25 million in Q4 2026. Management stated the estimate may change before the expected 2027 sales.
-
High exposure to cyclical industrial demand
Approximately 85% of revenue for the first three quarters of 2026 came from Industrial Solutions and industrial applications. Management notes that capital equipment spending is cyclical and can experience sudden and severe downturns.
-
Tariff benefits may not recur
The quarter's gross-margin improvement included an approximately 170-basis-point benefit from tariff activity, including $5.8 million of recoveries. Future recoveries are uncertain, while tariffs and retaliatory measures could adversely affect costs and operating results.
-
Manufacturing absorption pressure
Unabsorbed manufacturing expenses increased by $11.1 million year over year in the quarter, and the company recorded $6.7 million of provisions for slow-moving, obsolete or excess inventory. Lower production volumes could further reduce fixed-cost absorption and margins.
-
Customer concentration risk
The five largest customers represented 20% of nine-month revenue, and one customer represented 12% of accounts receivable at September 30, 2026. A substantial reduction in purchases by a significant customer could adversely affect results.
Management's outlook
The 10-Q does not provide new quantitative revenue or EPS guidance. It does state that the Lumibird Medical acquisition is expected to require approximately $340.3 million of cash at closing in Q4 2026, plus potential earn-out payments of up to $56.7 million.
Earlier filings 2
10-Q · May 5, 2026
IPG Photonics Corporation reported Q1 2026 results with revenues of $265.5 million, reflecting a 16.6% increase year-over-year, while diluted EPS was $0.29, missing expectations of $0.31. Notable growth was seen in the…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.